Ex vivo evaluation of blood coagulation on endothelial glycocalyx-inspired surfaces using thromboelastography
Tóm tắt
Present blood-contacting materials have not yet demonstrated to be effective in reducing blood coagulation without causing additional side effects clinically. We have developed an endothelial glycocalyx-inspired biomimetic surface that combines nanotopography, heparin presentation, and nitric oxide (NO)-releasing features. The resulting modified surfaces have already shown promise in reducing unfavorable blood-material interactions using platelet-rich plasma. In this study, the efficacy of modified surfaces for reducing coagulation of human whole blood was measured. In addition, the effects of leached polysaccharides and chemical modification of the modified surfaces were evaluated. Leached polysaccharides in the incubation solution were detected by a refractive index method to determine the potential influences of these modified surfaces on the blood coagulation observation. Chemical modifications by the nitrosation process on the polysaccharides in the modified surfaces were detected using attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR). Clot formation parameters were measured using thromboelastography (TEG), a clinically relevant technique to evaluate whole blood coagulation. No polysaccharides were detected in the heparinized polyelectrolyte multilayer-coated titania nanotube array surface (TiO2NT + PEM) incubation solution; however, polysaccharides were detected from NO-releasing TiO2NT + PEM surface (TiO2NT + PEM + NO) incubation solution both after the nitrosation process and after all NO was released. The structures of thiolated chitosan and heparin were altered by t-butyl nitrite. All heparin-containing surfaces were shown to slow or inhibit clot formation. This study is the first to evaluate these endothelial glycocalyx-inspired surfaces using clinically relevant parameters, as well as proposing potential influences of these modified surfaces on the inhibition of clot formation.
Tài liệu tham khảo
Lane WA. Some Remarks on the Treatment of Fractures. BMJ. 1895;1(1790):861–3.
Özcan M, Hämmerle C. Titanium as a Reconstruction and Implant Material in Dentistry: Advantages and Pitfalls. Materials (Basel). 2012;5(9):1528–45.
Balamurugan A, Rajeswari S, Balossier G, Rebelo AHS, Ferreira JMF. Corrosion aspects of metallic implants - An overview. Mater Corros. 2008;59(11):855–69.
Chen Q, Thouas GA. Metallic implant biomaterials. Mater Sci Eng R Reports. 2015;87:1–57.
U.S. Food & Drug Administration, “Biological Responses to Metal Implants,” 2019.
Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25(26):5681–703.
Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it? J Thromb Haemost. 2015;13(S1):S72–81.
Shabalovskaya S, Anderegg J, Van Humbeeck J. Critical overview of Nitinol surfaces and their modifications for medical applications. Acta Biomater. 2008;4(3):447–67.
Smith BS, Yoriya S, Grissom L, Grimes CA, Popat KC. Hemocompatibility of titania nanotube arrays. J Biomed Mater Res Part A. 2010;95A(2):350–60.
Smith BS, Popat KC. Titania Nanotube Arrays as Interfaces for Blood-Contacting Implantable Devices: A Study Evaluating the Nanotopography-Associated Activation and Expression of Blood Plasma Components. J Biomed Nanotechnol. 2012;8(4):642–58.
Shah Z, Masoomi R, Tadros P. Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation. J Atr Fibrillation. 2015;8(4):1318.
Thachil J, Gatt A, Martlew V. Management of surgical patients receiving anticoagulation and antiplatelet agents. Br J Surg. 2008;95(12):1437–48.
Mehran R, et al. Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent. Circulation. 2003;108(9):1078–83.
Di Mario C, et al. Single vs multivessel treatment during primary angioplasty: Results of the multicentre randomised HEpacoatTM for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Intervent. 2004;6(3–4):128–33.
Kocsis JF, Llanos G, Holmer E. Heparin-Coated stents. J Long Term Eff Med Implants. 2000;10(1–2):19–45.
Lappegård KT, et al. Effect of complement inhibition and heparin coating on artificial surface–induced leukocyte and platelet activation. Ann Thorac Surg. 2004;77(3):932–41.
Finn AV, et al. Vascular Responses to Drug Eluting Stents. Arterioscler Thromb Vasc Biol. 2007;27(7):1500–10.
Simon-Walker R, et al. Glycocalyx-Inspired Nitric Oxide-Releasing Surfaces Reduce Platelet Adhesion and Activation on Titanium. ACS Biomater Sci Eng. 2017;3(1):68–77.
Hedayati M, Kipper MJ. Atomic force microscopy of adsorbed proteoglycan mimetic nanoparticles: Toward new glycocalyx-mimetic model surfaces. Carbohydr Polym. 2018;190:346–55.
Hedayati M, Reynolds MM, Krapf D, Kipper MJ. Nanostructured Surfaces That Mimic the Vascular Endothelial Glycocalyx Reduce Blood Protein Adsorption and Prevent Fibrin Network Formation. ACS Appl Mater Interfaces. 2018;10(38):31892–902.
Hedayati M, Marruecos DF, Krapf D, Kaar JL, Kipper MJ. Protein adsorption measurements on low fouling and ultralow fouling surfaces: a critical comparison of surface characterization techniques. Acta Biomater. 2020;102:169–80.
Sabino RM, Kauk K, Madruga LYC, Kipper MJ, Martins AF, Popat KC. Enhanced hemocompatibility and antibacterial activity on titania nanotubes with tanfloc/heparin polyelectrolyte multilayers. J Biomed Mater Res Part A. 2020;108(4):992–1005.
da Câmara PCF, et al. Polyelectrolyte multilayers containing a tannin derivative polyphenol improve blood compatibility through interactions with platelets and serum proteins. Mater Sci Eng C. 2020;112:110919.
Rosselli M, Keller PJ, Dubey RKK, Keller RJ, Dubey RKK. Role of nitric oxide in the biology, physiology and pathophysiology of reproduction. Hum Reprod Updat. 1998;4(1):3–24.
Lantvit SM, Barrett BJ, Reynolds MM. Nitric oxide releasing material adsorbs more fibrinogen. J Biomed Mater Res - Part A. 2013;101(11):3201–10.
Zang Y, Popat KC, Reynolds MM. Nitric oxide-mediated fibrinogen deposition prevents platelet adhesion and activation ARTICLES YOU MAY BE INTERESTED IN. Biointerphases. 2018;13(6):E403.
Major TC, et al. The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer. Biomaterials. 2010;31(10):2736–45.
Damodaran VB, Leszczak V, Wold KA, Lantvit SM, Popat KC, Reynolds MM. Anti-thrombogenic properties of a nitric oxide-releasing dextran derivative: evaluation of platelet activation and whole blood clotting kinetics. RSC Adv. 2013;3(46):24406–14.
Pant J, Goudie MJ, Hopkins SP, Brisbois EJ, Handa H. Tunable Nitric Oxide Release from S-Nitroso-N-acetylpenicillamine via Catalytic Copper Nanoparticles for Biomedical Applications. ACS Appl Mater Interfaces. 2017;9(18):15254–64.
Zang Y, Popat KC, Reynolds MM. Nitric oxide-mediated fibrinogen deposition prevents platelet adhesion and activation. Biointerphases. 2018;13(6):06E403.
Peng HT. Thromboelastographic study of biomaterials. J Biomed Mater Res Part B Appl Biomater. 2010;94B(2):469–85.
Roberts TR, Leslie DC, Cap AP, Cancio LC, Batchinsky AI. Tethered-liquid omniphobic surface coating reduces surface thrombogenicity delays clot formation and decreases clot strength ex vivo. J Biomed Mater Res Part B Appl Biomater. 2020;108(2):496–502.
Hawker MJ, Olver CS, Fisher ER. Modification of a commercial thromboelastography instrument to measure coagulation dynamics with three-dimensional biomaterials. Biointerphases. 2016;11(2):29602.
Ouyang Y, et al. Qualitative and quantitative analysis of heparin and low molecular weight heparins using size exclusion chromatography with multiple angle laser scattering/refractive index and inductively coupled plasma/mass spectrometry detectors. J Chromatogr A. 2017;1522:56–61.
Sorkin JA, Hughes S, Soares P, Popat KC. Titania nanotube arrays as interfaces for neural prostheses. Mater Sci Eng C. 2015;49:735–45.
Yao C, Webster TJ. Anodization: a promising nano-modification technique of titanium implants for orthopedic applications. J Nanosci Nanotechnol. 2006;6(9–10):2682–92.
Minagar S, Wang J, Berndt CC, Ivanova EP, Wen C. Cell response of anodized nanotubes on titanium and titanium alloys. J Biomed Mater Res Part A. 2013;101A(9):2726–39.
Damodaran VB, Bhatnagar D, Leszczak V, Popat KC. Titania nanostructures: a biomedical perspective. RSC Adv. 2015;5(47):37149–71.
Popat KC, Eltgroth M, LaTempa TJ, Grimes CA, Desai TA. Titania nanotubes: A novel platform for drug-eluting coatings for medical implants? Small. 2007;3(11):1878–81.
Cowden K, Dias-Netipanyj MF, Popat KC. Effects of titania nanotube surfaces on osteogenic differentiation of human adipose-derived stem cells. Nanomedicine. 2019;17:380–90.
Vaughn MW, Kuo L, Liao JC. Estimation of nitric oxide production and reaction rates in tissue by use of a mathematical model. Am J Physiol - Hear Circ Physiol. 1998;274(6):43–6.
Skrzypchak AM, et al. Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation. Perfusion. 2007;22(3):193–200.
Lutzke A, Pegalajar-Jurado A, Neufeld BH, Reynolds MM. Nitric oxide-releasing S-nitrosated derivatives of chitin and chitosan for biomedical applications. J Mater Chem B. 2014;2(42):7449–58.
Shively JE, Conrad HE. Formation of Anhydrosugars in the Chemical Depolymerization of Heparin. Biochemistry. 1976;15(18):3932–42.
Allison CL, Lutzke A, Reynolds MM. Examining the effect of common nitrosating agents on chitosan using a glucosamine oligosaccharide model system. Carbohydr Polym. 2019;203:285–91.
Vilar RE, et al. Nitric oxide degradation of heparin and heparan sulphate. Biochem J. 1997;324(2):473–9.
Vlcek JR, Hedayati M, Melvin AC, Reynolds MM, Kipper MJ. Blood-compatible materials: vascular endothelium-mimetic surfaces that mitigate multiple cell-material interactions. Adv Healthc Mater. 2021;10(7):2001748.
Oduah E, Linhardt R, Sharfstein S. Heparin: past, present, and future. Pharmaceuticals. 2016;9(3):38.
Linhardt R, Murugesan S, Xie J. Immobilization of heparin: approaches and applications. Curr Top Med Chem. 2008;8(2):80–100.
Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth. 2009;13(3):154–75.
Brandenberg G, Leibrock LG, Shuman R, Malette WG, Quigley H. Chitosan: a new topical hemostatic agent for diffuse capillary bleeding in brain tissue. Neurosurgery. 1984;15(1):9–13.
Rao SB, Sharma CP. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res. 1997;34(1):21–8.
Benesch J, Tengvall P. Blood protein adsorption onto chitosan. Biomaterials. 2002;23(12):2561–8.
Okamoto Y, Yano R, Miyatake K, Tomohiro I, Shigemasa Y, Minami S. Effects of chitin and chitosan on blood coagulation. Carbohydr Polym. 2003;53(3):337–42.
Wedmore I, McManus JG, Pusateri AE, Holcomb JB. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma - Inj Infect Crit Care. 2006;60(3):655–8.
Ong SY, Wu J, Moochhala SM, Tan MH, Lu J. Development of a chitosan-based wound dressing with improved hemostatic and antimicrobial properties. Biomaterials. 2008;29(32):4323–32.
Hattori H, Ishihara M. Changes in blood aggregation with differences in molecular weight and degree of deacetylation of chitosan. Biomed Mater. 2015;10(1):015014.
Mirzadeh H, Yaghobi N, Amanpour S, Ahmadi H, Mohagheghi MA, Hormozi F. Preparation of chitosan derived from shrimp’s shell of Persian gulf as a blood hemostasis agent. Iran Polym J. 2002;11(1):63–8.
Chou TC, Fu E, Wu CJ, Yeh JH. Chitosan enhances platelet adhesion and aggregation. Biochem Biophys Res Commun. 2003;302(3):480–3.
Sagnella S, Mai-Ngam K. Chitosan based surfactant polymers designed to improve blood compatibility on biomaterials. Colloids Surfaces B Biointerfaces. 2005;42(2):147–55.
Lord MS, Cheng B, McCarthy SJ, Jung MS, Whitelock JM. The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins. Biomaterials. 2011;32(28):6655–62.
Hu Z, Zhang D-Y, Lu S-T, Li P-W, Li S-D. Chitosan-based composite materials for prospective hemostatic applications. Mar Drugs. 2018;16(8):273.
Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;330(8567):1057–8.
Radomski MW, Moncada S. The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol. 1993;344:251–64.
Fleser PS, et al. Nitric oxide-releasing biopolymers inhibit thrombus formation in a sheep model of arteriovenous bridge grafts. J Vasc Surg. 2004;40(4):803–11.
Archer S. Measurement of nitric oxide in biological models. FASEB J. 1993;7(2):349–60.
Hakim TS, Sugimori K, Camporesi EM, Anderson G. Half-life of nitric oxide in aqueous solutions with and without haemoglobin. Physiol Meas. 1996;17(4):267–77.
Scarpelini S, et al. Normal range values for thromboelastography in healthy adult volunteers. Braz J Med Biol Res. 2009;42(12):1210–7.
Othman M, Kaur H. Thromboelastography (TEG). Methods Mol Biol. 2017;1646:533–43.
Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis. 2003;16(1–2):17–20.
Roberts H, Hoffman M, Monroe D. A Cell-Based Model of Thrombin Generation. Semin Thromb Hemost. 2006;32(S 1):032–8.
Mackman N, Tilley RE, Key NS. Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687–93.
Smith SA. The cell-based model of coagulation. J vet Emerg Crit Care. 2009;19(1):3–10.
Sanchez J, Elgue G, Riesenfeld J, Olsson P. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb Res. 1998;89(1):41–50.